Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

Journal of Diabetes Investigation
Onno N GroeneveldGeert Jan Biessels

Abstract

Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia. Furthermore, their risk of stroke is increased and their outcome after stroke is worse than in those without diabetes. Incretin-based therapies are a class of antidiabetic agents that are of interest in relation to these cerebral complications of diabetes. Two classes of incretin-based therapies are currently available: the glucagon-like-peptide-1 agonists and the dipeptidyl peptidase-4 -inhibitors. Independent of their glucose-lowering effects, incretin-based therapies might also have direct or indirect beneficial effects on the brain. In the present review, we discuss the potential of incretin-based therapies in relation to dementia, in particular Alzheimer's disease, and stroke in patients with type 2 diabetes. Experimental studies on Alzheimer's disease have found beneficial effects of incretin-based therapies on cognition, synaptic plasticity and metabolism of amyloid-β and microtubule-associated protein tau. Preclinical studies on incretin-based therapies in stroke have shown an improved functional outcome, a reduction of infarct volume as well as neuroprotective and neurotrophic properties. Both with regard to the treatment...Continue Reading

References

Oct 6, 2001·Stroke; a Journal of Cerebral Circulation·S E CapesH C Gerstein
Apr 5, 2002·Journal of Molecular Neuroscience : MN·Abba J KastinWeihong Pan
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·TracyAnn PerryNigel H Greig
Mar 8, 2003·Stroke; a Journal of Cerebral Circulation·Salah-Eddine MegherbiUNKNOWN European BIOMED Study of Stroke Care Group
Mar 12, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A J Kastin, V Akerstrom
Aug 20, 2003·Nature Medicine·Matthew J DuringColin N Haile
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénAnja Schweizer
Feb 18, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jenny NybergPeter S Eriksson
Jul 25, 2006·Expert Opinion on Investigational Drugs·Claudio GonzálezGuillermo Di Girolamo
Oct 19, 2006·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Jianhui LiuHeng Zhang
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
May 10, 2008·European Journal of Pharmacology·Victor A Gault, Christian Hölscher
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jul 29, 2008·Stroke; a Journal of Cerebral Circulation·Masoor KamaleshGeorge J Eckert
Oct 14, 2008·Biochimica Et Biophysica Acta·Esther van den BergGeert Jan Biessels
Nov 22, 2008·Stroke; a Journal of Cerebral Circulation·J Marc SimardVolodymyr Gerzanich
Dec 18, 2008·The Journal of Clinical Endocrinology and Metabolism·Michael BoschmannJens Jordan
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yazhou LiNigel H Greig
May 26, 2009·Lancet·Kathleen M DunganJean-Charles Preiser
Jun 30, 2009·Biopharmaceutics & Drug Disposition·Holger FuchsAndreas Greischel
Aug 26, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Denise D BelshamMargaret M Koletar
Dec 17, 2009·Experimental Gerontology·Michele D'AmicoGiuseppe Paolisso
Dec 29, 2009·European Journal of Pharmacology·Paula L McCleanChristian Hölscher
Feb 5, 2010·British Journal of Pharmacology·Alexander Harkavyi, Peter S Whitton
Feb 17, 2010·Nature Reviews. Neurology·Nyika D KruytYvo B Roos
Mar 31, 2010·International Journal of Obesity : Journal of the International Association for the Study of Obesity·V A GaultC Hölscher
Apr 3, 2010·Neurobiology of Aging·Simon GenglerChristian Hölscher
May 25, 2010·Cellular and Molecular Life Sciences : CMLS·Paola LucianiAlessandro Peri

❮ Previous
Next ❯

Citations

Nov 26, 2016·The American Journal of Case Reports·Yoshihiro SaitoKazumasa Harada
May 4, 2017·World Journal of Diabetes·Aikaterini TrikkalinouAndreas Melidonis
Jun 15, 2017·The Journal of Endocrinology·Paul MillarVictor A Gault
May 24, 2019·Acta Diabetologica·Nikolaus BuchmannElisabeth Steinhagen-Thiessen
Mar 10, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·James M FitzGeraldDavid J Meagher
Apr 24, 2019·The Cochrane Database of Systematic Reviews·Rebecca WoodhouseNajma Siddiqi
Dec 19, 2018·Gerontology & Geriatric Medicine·Andrzej LewandowiczPaweł Piątkiewicz
Mar 7, 2020·The Lancet. Diabetes & Endocrinology·Thomas T van SlotenCoen D A Stehouwer
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mohamed Faisal LutfiMansour Alsharidah
Jun 4, 2021·Journal of Biomolecular Structure & Dynamics·Suman ManandharK Sreedhara Ranganath Pai
Apr 27, 2021·British Journal of Pharmacology·Christian Hölscher

❮ Previous
Next ❯

Methods Mentioned

BETA
amputations

Clinical Trials Mentioned

NCT01255163
NCT01843075
NCT00968708
NCT01107886
NCT00790205
NCT01147250
NCT01179048
NCT01243424
NCT01394952
NCT01897532

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.